Medtronic plc [MDT] vs Dexcom [DXCM] Detailed Stock Comparison
Medtronic plc
NYSE
Loading...
Dexcom
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Medtronic plc wins in 15 metrics, Dexcom wins in 4 metrics, with 0 ties. Medtronic plc appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Medtronic plc | Dexcom | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 25.72 | 56.46 | Medtronic plc |
| Price-to-Book Ratio | 2.48 | 12.22 | Medtronic plc |
| Debt-to-Equity Ratio | 61.39 | 100.24 | Medtronic plc |
| PEG Ratio | 15.87 | 39.49 | Medtronic plc |
| EV/EBITDA | 15.24 | 33.67 | Medtronic plc |
| Profit Margin (TTM) | 13.90% | 13.29% | Medtronic plc |
| Operating Margin (TTM) | 17.09% | 18.37% | Dexcom |
| EBITDA Margin (TTM) | 17.09% | 18.37% | Dexcom |
| Return on Equity | 9.51% | 22.83% | Dexcom |
| Return on Assets (TTM) | 4.41% | 6.08% | Dexcom |
| Free Cash Flow (TTM) | $5.19B | $630.70M | Medtronic plc |
| Dividend Yield | 3.27% | N/A | N/A |
| 1-Year Return | 9.95% | 8.44% | Medtronic plc |
| Price-to-Sales Ratio (TTM) | 3.55 | 7.31 | Medtronic plc |
| Enterprise Value | $138.87B | $31.09B | Medtronic plc |
| EV/Revenue Ratio | 4.14 | 7.23 | Medtronic plc |
| Gross Profit Margin (TTM) | 64.75% | 59.53% | Medtronic plc |
| Revenue per Share (TTM) | $26 | $11 | Medtronic plc |
| Earnings per Share (Diluted) | $3.61 | $1.42 | Medtronic plc |
| Beta (Stock Volatility) | 0.82 | 1.44 | Medtronic plc |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Medtronic plc vs Dexcom Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Medtronic plc | 1.13% | 0.15% | 4.26% | 8.02% | 8.07% | 15.96% |
| Dexcom | 1.24% | 2.65% | -4.52% | -5.51% | -10.58% | 3.12% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Medtronic plc | 9.95% | -2.08% | -5.78% | 25.25% | 167.53% | 67.45% |
| Dexcom | 8.44% | -4.89% | -24.15% | 259.78% | 2,494.55% | 2,653.40% |
Performance & Financial Health Analysis: Medtronic plc vs Dexcom
| Metric | MDT | DXCM |
|---|---|---|
| Market Information | ||
| Market Cap | $118.98B | $31.44B |
| Market Cap Category | Large cap | Large cap |
| 10 Day Avg. Volume | 6,174,214 | 5,083,030 |
| 90 Day Avg. Volume | 6,491,491 | 3,546,350 |
| Last Close | $93.02 | $80.95 |
| 52 Week Range | $79.29 - $96.25 | $57.52 - $93.25 |
| % from 52W High | -3.36% | -13.19% |
| All-Time High | $135.89 (Sep 06, 2021) | $164.86 (Nov 15, 2021) |
| % from All-Time High | -31.55% | -50.90% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.04% | 0.15% |
| Quarterly Earnings Growth | 0.62% | 0.25% |
| Financial Health | ||
| Profit Margin (TTM) | 0.14% | 0.13% |
| Operating Margin (TTM) | 0.17% | 0.18% |
| Return on Equity (TTM) | 0.10% | 0.23% |
| Debt to Equity (MRQ) | 61.39 | 100.24 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $37.46 | $6.56 |
| Cash per Share (MRQ) | $7.00 | $7.47 |
| Operating Cash Flow (TTM) | $7.04B | $987.70M |
| Levered Free Cash Flow (TTM) | $4.21B | $425.12M |
| Dividends | ||
| Last 12-Month Dividend Yield | 3.27% | N/A |
| Last 12-Month Dividend | $2.80 | N/A |
Valuation & Enterprise Metrics Analysis: Medtronic plc vs Dexcom
| Metric | MDT | DXCM |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 25.72 | 56.46 |
| Forward P/E | 15.87 | 39.49 |
| PEG Ratio | 15.87 | 39.49 |
| Price to Sales (TTM) | 3.55 | 7.31 |
| Price to Book (MRQ) | 2.48 | 12.22 |
| Market Capitalization | ||
| Market Capitalization | $118.98B | $31.44B |
| Enterprise Value | $138.87B | $31.09B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 4.14 | 7.23 |
| Enterprise to EBITDA | 15.24 | 33.67 |
| Risk & Other Metrics | ||
| Beta | 0.82 | 1.44 |
| Book Value per Share (MRQ) | $37.46 | $6.56 |
Financial Statements Comparison: Medtronic plc vs Dexcom
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | MDT | DXCM |
|---|---|---|
| Revenue/Sales | $8.93B | $1.04B |
| Cost of Goods Sold | $3.15B | $447.00M |
| Gross Profit | $5.78B | $589.00M |
| Research & Development | $684.00M | $145.20M |
| Operating Income (EBIT) | $1.80B | $133.70M |
| EBITDA | $2.64B | $219.00M |
| Pre-Tax Income | $1.26B | $154.30M |
| Income Tax | $199.00M | $48.90M |
| Net Income (Profit) | $1.06B | $105.40M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | MDT | DXCM |
|---|---|---|
| Cash & Equivalents | $2.22B | $904.90M |
| Total Current Assets | $23.81B | $4.55B |
| Total Current Liabilities | $12.88B | $3.04B |
| Long-Term Debt | $25.64B | $1.36B |
| Total Shareholders Equity | $48.26B | $2.27B |
| Retained Earnings | $31.48B | $1.70B |
| Property, Plant & Equipment | $7.16B | $59.10M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | MDT | DXCM |
|---|---|---|
| Operating Cash Flow | $2.14B | $167.90M |
| Capital Expenditures | $-459.00M | $-87.00M |
| Free Cash Flow | $2.07B | $96.80M |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | $-274.00M | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | MDT | DXCM |
|---|---|---|
| Shares Short | 11.60M | 8.49M |
| Short Ratio | 1.67 | 2.71 |
| Short % of Float | 0.01% | 0.03% |
| Average Daily Volume (10 Day) | 6,174,214 | 5,083,030 |
| Average Daily Volume (90 Day) | 6,491,491 | 3,546,350 |
| Shares Outstanding | 1.28B | 390.70M |
| Float Shares | 1.28B | 389.43M |
| % Held by Insiders | 0.00% | 0.00% |
| % Held by Institutions | 0.87% | 0.99% |
Dividend Analysis & Yield Comparison: Medtronic plc vs Dexcom
| Metric | MDT | DXCM |
|---|---|---|
| Last 12-Month Dividend | $2.80 | N/A |
| Last 12-Month Dividend Yield | 3.27% | N/A |
| 3-Year Avg Annual Dividend | $2.76 | N/A |
| 3-Year Avg Dividend Yield | 0.83% | N/A |
| 3-Year Total Dividends | $8.28 | N/A |
| Ex-Dividend Date | Mar 28, 2025 | N/A |